Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
Plasma levels of the dopamine metabolite homovanillic acid (pHVA) may potentially reflect upon central dopamine activity. This study examines the effects of debrisoquin, haloperidol, and the two drugs combined on pHVA concentrations of schizophrenic patients. Debrisoquin is a drug that suppresses the peripheral formation of homovanillic acid without affecting the central formation. Acute haloperidol administration consistently increased pHVA concentrations in patients pretreated or not pretreated with debrisoquin, suggesting that this increment reflects haloperidol's central and not peripheral effects.
D000328:Adult; D003647:Debrisoquin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000627:therapeutic use*; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D007546:Isoquinolines; D006220:Haloperidol; D003647:Debrisoquin; D006719:Homovanillic Acid